- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01178957
Very-Low-Density-Lipoprotein-Triglyceride(VLDL-TG) Metabolism During Acute Hyperglycemia
August 5, 2013 updated by: University of Aarhus
The purpose of this study is to estimate the acute effect of hyperglycemia on Very-Low-Density-Lipoprotein-triglyceride(VLDL-TG) secretion.
Study Overview
Study Type
Observational
Enrollment (Actual)
8
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Aarhus C, Denmark, 8000
- Department of Endocrinology MEA, Aarhus Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Sampling Method
Non-Probability Sample
Study Population
Type 1 diabetics
Description
Inclusion Criteria:
- Type 1 diabetes
- Age 18-50 years
Exclusion Criteria:
- Smoking
- Alcohol abuse
- Use of medications (except insulin in diabetics)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Type 1 diabetes
|
Hyperglycemia with a blood glucose of 15 mmol/L
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Very-Low-Density-Lipoprotein-Triglyceride(VLDL-TG) secretion
Time Frame: 8 hours
|
Very-Low-Density-Lipoprotein-Triglyceride(VLDL-TG) kinetics over a single study day
|
8 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2012
Primary Completion (Actual)
April 1, 2013
Study Completion (Actual)
April 1, 2013
Study Registration Dates
First Submitted
April 21, 2010
First Submitted That Met QC Criteria
August 9, 2010
First Posted (Estimate)
August 10, 2010
Study Record Updates
Last Update Posted (Estimate)
August 7, 2013
Last Update Submitted That Met QC Criteria
August 5, 2013
Last Verified
August 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ES-0004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Rabin Medical CenterDreaMed DiabetesTerminated
Clinical Trials on Hyperglycemia
-
Chang Gung Memorial HospitalCompletedHyperglycemia | Thoracic Injury | Abdominal Injury | Hyperglycemia StressTaiwan
-
Rigshospitalet, DenmarkWithdrawn
-
University of MinnesotaRecruiting
-
University of BirminghamCompletedHyperglycemia | Aerobic Exercise | Glucose Metabolism Disorders (Including Diabetes Mellitus)United Kingdom
-
Insel Gruppe AG, University Hospital BernIdiap Research Institute; CSEM Centre Suisse d'Electronique et de Microtechnique...Not yet recruitingDiabetes MellitusSwitzerland
-
Hadassah Medical OrganizationCompletedHyperglycemia | DiabetesIsrael
-
Steno Diabetes Center CopenhagenActive, not recruitingHyperglycemia | Cardiovascular Diseases | Hypoglycemia | Diabetes | Sudden Cardiac DeathDenmark
-
Novartis PharmaceuticalsRecruiting
-
Women's Hospital School Of Medicine Zhejiang UniversityActive, not recruitingGestational Diabetes Mellitus in PregnancyChina
-
Jaeb Center for Health ResearchNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedHyperglycemia | Hypoglycemia | Type 1 Diabetes | Artificial PancreasUnited States